Ningxia Zhongke Biotechnology Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Rui Chen

Chief executive officer

CN¥264.5k

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	2.3yrs

Recent management updates

Recent updates

Revenues Not Telling The Story For Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) After Shares Rise 25%

Nov 13

What Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 34% Share Price Gain Is Not Telling You

Aug 30

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Looks Just Right With A 50% Price Jump

Jul 12

Calculating The Intrinsic Value Of Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165)

Jun 03

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Shares Slammed 30% But Getting In Cheap Might Be Difficult Regardless

Apr 21

Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 29% Cheaper Price Remains In Tune With Revenues

Feb 27

CEO

Rui Chen (50 yo)

no data

Tenure

CN¥264,500

Compensation

Mr. Rui Chen serves as General Manager of Ningxia Zhongke Biotechnology Co., Ltd. and served as its Director until July 01, 2022. Mr. Chen served as Chief Financial Officer of Ningxia Zhongke Biotechnology...

Board Members

Name	Position	Tenure	Compensation	Ownership
Baoqing Shentu	Independent Director	2.3yrs	CN¥33.30k	no data
Xiufeng Yue	Independent Director	2.3yrs	CN¥80.00k	no data
Can Ting Zhu	Director	2.3yrs	no data	no data
Cun Zai Han	Chairman of the Supervisory Board	no data	no data	no data
Xu Ran	Supervisor	no data	no data	no data
Chao Lin	Director	2.3yrs	no data	no data
Yijie Lou	Independent Director	2.3yrs	CN¥33.30k	no data
Jiangming Wu	Director	2.9yrs	no data	no data
Jinxin Zhang	Supervisor	2.6yrs	no data	no data
Chun hai Hu	Chairman	2.3yrs	no data	no data
Xinling Wang	Independent Director	2.3yrs	CN¥80.00k	no data

2.3yrs

Average Tenure

54yo

Average Age

Experienced Board: 600165's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Ningxia Zhongke Biotechnology Management

Management criteria checks 2/4

Key information

Recent management updates

Ningxia Zhongke Biotechnology Co., Ltd, Annual General Meeting, May 17, 2024

Ningxia Zhongke Biotechnology Co., Ltd, Annual General Meeting, May 17, 2024

Insufficient new directors

Less than half of directors are independent

Recent updates

Revenues Not Telling The Story For Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) After Shares Rise 25%

Third quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.12 loss in 3Q 2023)

Ningxia Zhongke Biotechnology Co., Ltd to Report Q3, 2024 Results on Oct 31, 2024

What Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 34% Share Price Gain Is Not Telling You

Second quarter 2024 earnings released: CN¥0.55 loss per share (vs CN¥0.12 loss in 2Q 2023)

Now 21% overvalued after recent price rise

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Looks Just Right With A 50% Price Jump

Now 27% overvalued

Ningxia Zhongke Biotechnology Co., Ltd to Report First Half, 2024 Results on Aug 15, 2024

Now 24% overvalued

Now 21% overvalued

Calculating The Intrinsic Value Of Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165)

Now 23% overvalued

Ningxia Zhongke Biotechnology Co., Ltd(SHSE:600165) dropped from Shanghai Stock Exchange Composite Index

Ningxia Zhongke Biotechnology Co., Ltd, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.68 loss per share (vs CN¥0.21 loss in FY 2022)

Ningxia Zhongke Biotechnology Co., Ltd, Annual General Meeting, May 17, 2024

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Shares Slammed 30% But Getting In Cheap Might Be Difficult Regardless

Ningxia Zhongke Biotechnology Co., Ltd to Report Q1, 2024 Results on Apr 30, 2024

Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 29% Cheaper Price Remains In Tune With Revenues

Ningxia Zhongke Biotechnology Co., Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released

Ningxia Zhongke Biotechnology Co., Ltd to Report Q3, 2023 Results on Oct 28, 2023

New major risk - Financial position

Second quarter 2023 earnings released: CN¥0.12 loss per share (vs CN¥0.046 profit in 2Q 2022)

Ningxia Zhongke Biotechnology Co., Ltd. to Report First Half, 2023 Results on Aug 15, 2023

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.034 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released

Ningxia Xinri Hengli Steel Wire Rope Co., Ltd (SHSE:600165) entered into an agreement to acquire 10% stake in Ningxia Hengli Biological New Material Co., Ltd. from Shizuishan Zhengxingcheng New Material Technology Partnership Enterprise (Limited Partnership) for CNY 106 million.

Full year 2021 earnings released: CN¥0.034 loss per share (vs CN¥0.031 profit in FY 2020)

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.005 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.02 loss per share (vs CN¥0.012 loss in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.031 (vs CN¥0.066 loss in FY 2019)

New 90-day low: CN¥5.82

New 90-day low: CN¥6.71

New 90-day high: CN¥8.42

Third quarter earnings released

Shizuishan Zhengxingcheng New Material Technology Partnership Enterprise (Limited Partnership) agreed to acquire 10% stake in Ningxia Hengli Biological New Material Co., Ltd. from Ningxia Xinri Hengli Steel Wire Rope Co.,Ltd (SHSE:600165).

First half earnings released

First half earnings released

New 90-day high - CN¥8.15

Ningxia Xinri Hengli Steel Wire Rope Co.,Ltd to Report First Half, 2020 Results on Aug 21, 2020

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age